MarketBeat
26 Sept 2026, 08:03 UTC · 4h ago
Verdict
Headline takes no side. We score BBIO +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 0 new · 5 priced in
Attruby is annualizing at more than $1 billion globally and is expected to reach full-year blockbuster status by the end of 2026.
Priced indiscussion during a Bernstein event
So whatIncremental quarterly revenue growth of $25M-$30M suggests an additional $100M-$120M in annual run-rate by end of 2026.
More positive than 93% of claims this week
BridgeBio expects an FDA decision on BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9 on or before Nov. 27, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced indiscussion during a Bernstein event
So whatThe initial U.S. launch pool of 500 identified patients provides a baseline for near-term revenue estimates post-approval.
More positive than 87% of claims this week
Encaleret for autosomal dominant hypocalcemia type 1 has a PDUFA date of May 8.
Priced indiscussion during a Bernstein event
So whatApproval would trigger a transition from R&D to commercial stage for this asset within the current fiscal year.
More positive than 79% of claims this week
BridgeBio projects peak-year sales for acoramidis (Attruby) to exceed $4 billion.
Priced indiscussion during a Bernstein event
So whatA 4x increase from current $1B annualization suggests significant headroom as it captures more of the 15k-16k annual patient funnel.
More positive than 65% of claims this week
A once-daily formulation of Attruby could enter the clinic within 12 to 18 months.
Priced indiscussion during a Bernstein event
So whatLifecycle management typically extends patent protection and prevents generic erosion beyond the original 2027-2030 horizon.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
Strong revenue growth for Attruby, positive Phase 3 trial data for upcoming launches, and a clear growth strategy toward 2027.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
—
BBIO hasn't traded since this ran. Last close $65.57 (Sep 25); the reaction starts at the next open.
BBIO chart →
